{"@id":"https://bioecon.ru/technology/recombinant-proteins-for-dermatology-oncology/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/recombinant-proteins-for-dermatology-oncology/","json":"https://en.bioecon.ru/api/v1/technology/recombinant-proteins-for-dermatology-oncology/index.json"},"id":"recombinant-proteins-for-dermatology-oncology","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/dyadic-international/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/loopworm/","https://bioecon.ru/companies/spiber-technologies-ab/","https://bioecon.ru/companies/jiangsu-trautec/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/isomerase/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/giant-biogene-holding/","https://bioecon.ru/companies/gilead-sciences/"]},"maturity":7,"name":"Recombinant Proteins for Dermatology and Oncology","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Engineered matricellular variants"},{"n":2,"title":"Topical penetration formulation"},{"n":3,"title":"Tissue regeneration acceleration"},{"n":4,"title":"Intratumoral stroma normalization"}],"summary":"Engineered recombinant human growth factors, matricellular proteins, and cytokines formulated for topical, transdermal, or intra-tumoral administration, accelerating severe wound re-epithelialization or reprogramming desmoplastic cancer stroma.","url":"/technology/recombinant-proteins-for-dermatology-oncology/","verified":"2026-11-22"}